On November 10 Dimas Covas, the head of the research institute that cooperated with China Kexing Company to carry out the third phase of human trials coronavirus vaccine in Brazil, said at a press conference in Sao Paulo, Brazil that there are currently participating trials. The “serious adverse reaction” of the virus has nothing to do with coronavirus vaccine injection.
Dimas Covas is the director of the Butantan Institute, an authoritative Brazilian biomedical research institution, and the main person in charge of the Brazilian side who represented the state of São Paulo to cooperate with Chinese companies in coronavirus vaccine trial. He said he was “surprised” that the current clinical trial of the vaccine was stopped by Brazil’s National Health Supervision Agency (Anvisa).
The Brazilian National Health Supervision Agency (Anvisa), which is responsible for medical and health supervision, announced on November 9th local time that a clinical trial of coronavirus vaccine between China Kexing Company and the Butantan Institute in Sao Paulo State had a case on October 29 The tester had “serious adverse reactions” and therefore decided to suspend the Phase III clinical trial of the vaccine in Brazil. In response, Kovas responded on the 10th that he had sent vaccine test data and other materials to the National Health Supervision Bureau, which can prove that the “serious adverse reaction” has nothing to do with the vaccine. He also said that “the vaccine is currently under development in the world.
The safest coronavirus vaccine
No other country that has conducted trials of this vaccine has announced a suspension of trials. In consideration of protecting the information of participants in the trial, neither the Brazilian National Health Supervision Agency and the Butantin Institute have specified the specific symptoms and causes of the trial participants’ “serious adverse reactions”.
Brazil currently has more than 5.6 million confirmed cases of coronavirus pandemic, making it the country with the worst outbreak in Latin America. Because the vaccine is one of the earliest vaccines that are expected to be released locally, the suspension of the trial has attracted great attention from all walks of life in Brazil. The vaccine has been tested in cooperation in the State of Sao Paulo, Brazil since July. At the end of September, the Sao Paulo State Government and the Butantin Institute stated that the test results up to that time showed that the vaccine was “effective as high as 98%, and 94.7% of vaccinators had no adverse reactions.”
The Brazilian Health Supervision Agency officially authorized the Butantan Institute to import 6 million doses of coronavirus vaccine on October 23. On October 28, the Health Supervision Bureau again approved the Butantan Institute to import raw materials for the production of coronavirus vaccine from China.
The vaccine factory in São Paulo State and the Butantan Institute plan to use these raw materials to produce 40 million doses of coronavirus vaccine locally. The governor of São Paulo State, Doria, has stated that he hopes to vaccinate everyone in the state as early as March next year.
Previously, due to adverse reactions in human trials, clinical trials of a coronavirus vaccine developed by the United Kingdom in Brazil were suspended on September 8 and subsequently resumed on September 13.